Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Grace Therapeutics, Inc
Bullboard Posts
User Avatar Image
(2)
•••
Post by LittleHedgeon Jun 27, 2019 2:00pm
98 Views
Post# 29870731

Mackie rates Spec buy PT $8.70 - research note

Mackie rates Spec buy PT $8.70 - research noteMackie sees sales potential of Acasti's CaPre drug, maintains Speculative Buy rating TP $8.70

10:45 27 Jun 2019
In a research note, Mackie wrote that the market is 'waking up' to the potential of CaPre, which treats severe hypertriglyceridemia

Complete article
https://ca.proactiveinvestors.com/companies/news/222977/mackie-sees-sales-potential-of-acasti-s-capre-drug-maintains-speculative-buy-rating-222977.html

 Mackie Research is maintaining a Speculative Buy rating on Acasti Pharma Inc (CVE:ACST) (NASDAQ:ACST) after the company posted its fiscal 2019 results showing it was well-funded to proceed with clinical trials.

The Laval, Quebec-based pharmaceutical company is advancing its lead drug CaPre, an omega-3 phospholipid to combat high levels of triglycerides, or fatty molecules.

The research firm set a price target of C$8.70 and said that CaPre’s sales potential is “highly underestimated” in a note on Thursday.

Link discusses funding, competitive advantages (over Lovaza and Amarin), and positive trial results
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities